The Technical Analyst
Outlook Therapeutics Inc [OTLK]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Outlook Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.00% $1.020
Last updated: 3 jul 2022 - 20:06
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 230.46 mill |
| EPS: | -0.322 |
| P/E: | 0.000 |
| Earnings Date: | Aug 11, 2022 |
| SharesOutstanding: | 225.94 mill |
| Avg Daily Volume: | 1.091 mill |
| RATING 2022-07-01 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.115 (9.30%) $0.0948 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $0.0970 ( +/- 9.51%) Range: 0.923 - 1.117 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-21 | Trenary C Russell Iii | Buy | 19 925 | Common Stock |
| 2022-06-21 | Dagnon Terry | Buy | 10 000 | Common Stock |
| 2022-04-21 | Biolexis Pte Ltd. | Sell | 27 982 529 | Common Stock |
| 2022-04-21 | Sukhtian Faisal Ghiath | Buy | 27 982 529 | Common Stock |
| 2022-03-31 | Evanson Jeff | Buy | 100 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 27.14 |
| Last 100 transactions |
| Buy: 115 181 106 | Sell: 30 763 880 |
Forecast:
16:00 - $1.030
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.030
Forecast 2: 16:00 - $1.030
Forecast 3: 16:00 - $1.030
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.020 (0.00% ) |
| Volume | 0.377 mill |
| Avg. Vol. | 1.091 mill |
| % of Avg. Vol | 34.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OTLK
50 Signals | Accuracy: 8.00% | Accuracy Buy: 12.00% | Accuracy Sell: 4.00%
Avg return buy: -0.50 % | Avg return sell: 0.45 %
$1 invested is now $0.88 or -11.78% since 30-06-22
| Date | Signal | @ | Closed | % | Jul 1 - 15:57 | sell | $1.025 | N/A | Active |
|---|---|---|---|---|
| Jul 1 - 15:56 | buy | $1.030 | $1.025 @ Jul 1 - 15:57 | -0.49% |
| Jul 1 - 15:46 | sell | $1.025 | $1.030 @ Jul 1 - 15:56 | 0.49% |
| Jul 1 - 15:41 | buy | $1.030 | $1.025 @ Jul 1 - 15:46 | -0.49% |
| Jul 1 - 15:37 | sell | $1.025 | $1.030 @ Jul 1 - 15:41 | 0.49% |
| Jul 1 - 15:30 | buy | $1.030 | $1.025 @ Jul 1 - 15:37 | -0.49% |
| Jul 1 - 15:29 | sell | $1.025 | $1.030 @ Jul 1 - 15:30 | 0.49% |
| Jul 1 - 15:18 | buy | $1.030 | $1.025 @ Jul 1 - 15:29 | -0.49% |
| Jul 1 - 15:15 | sell | $1.025 | $1.030 @ Jul 1 - 15:18 | 0.49% |
| Jul 1 - 14:20 | buy | $1.015 | $1.025 @ Jul 1 - 15:15 | 0.99% |
OTLK
Latest Press Releases
2022-05-13 08:05:00 - Press Release
Outlook Therapeutics Reports Financial Results For Second Quarter Fiscal Year 2022 And Provides Corporate Update
Iselin, n.j., may 13, 2022 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a pre-commercial biopharmaceutical company working to develop and launch the first fda-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended march 31, 2022.
2022-05-09 08:35:00 - Press Release
Outlook Therapeutics To Participate At The Virtual Investor 2022 Ceo Spotlight
Live moderated video webcast on wednesday, may 11th at 1:00 pm et live moderated video webcast on wednesday, may 11th at 1:00 pm et
2022-04-22 08:05:00 - Press Release
Biolexis Reorganization Results In Gms Holdings As Largest Shareholder In Outlook Therapeutics
Singapore and iselin, n.j., april 22, 2022 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a pre-commercial biopharmaceutical company working to develop and launch the first fda-approved ophthalmic formulation of bevacizumab for use in retinal indications, and biolexis pte ltd. (“biolexis”), a strategic shareholder in outlook therapeutics, today announced that biolexis is being reorganized. the biolexis reorganization, which does not entail any changes in the indirect ownership of outlook therapeutics, provides gms holdings with increased flexibility to support the future growth of outlook therapeutics as its largest shareholder.
2021-11-23 22:30:00 - Press Release
Outlook Therapeutics Increases Previously Announced Bought Deal Offering Of Common Stock To $50 Million
Iselin, n.j., nov. 23, 2021 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk) (“outlook therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the first fda-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 40,000,000 shares of common stock of outlook therapeutics, at a price to the public of $1.25 per share, less underwriting discounts and commissions. the closing of the offering is expected to occur on or about november 29, 2021, subject to satisfaction of customary closing conditions.
2021-11-13 11:00:00 - Press Release
Outlook Therapeutics Presents Norse Two Phase 3 Pivotal Safety And Efficacy Data For Ons-5010 / Lytenava™ (bevacizumab-vikg) At The Retina Subspecialty Day, American Academy Of Ophthalmology (aao) 2021 Annual Conference
- norse two showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data
Latest News
2022-06-14 09:08:48 - Proactive Investors
Outlook Therapeutics confirms BLA re-submission date for its ONS-5010 wet AMD treatment
Outlook Therapeutics (NASDAQ:OTLK) Inc has provided an update on its Biologics License Application (BLA) submission for ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). The pre-commercial biopharmaceutical company said it has confirmed the additional information necessary to re-submit the BLA for ONS-5010 by September 2022 following receipt of additional correspondence from the US Food and Drug Administration (FDA).
2022-06-09 14:27:50 - Seeking Alpha
Outlook Therapeutics: A One-Buck Lottery Ticket
Today, we revisit Outlook Therapeutics for the first time since March 2021. The company recently temporarily withdrew its marketing application for its main asset, clouding the outlook on this small-cap name even further.
2022-05-31 10:26:56 - Proactive Investors
Outlook Therapeutics opts to resubmit BLA for wet AMD drug after FDA requests more info
Outlook Therapeutics (NASDAQ:OTLK) Inc said it has voluntarily withdrawn the biologics license application (BLA) for its ophthalmic formulation of bevacizumab (ONS-5010 or Lytenava) after the US Food and Drug Administration (FDA) requested additional information. The company added that it is actively working to respond to the FDA's request and plans to resubmit a revised BLA by September.
2022-05-18 08:05:00 - GlobeNewsWire
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
2022-05-13 10:26:16 - Proactive Investors
Outlook Therapeutics ends fiscal 2Q with $58.4M in cash as it ramps up pre-commercial activities for wet AMD treatment Lytenava
Outlook Therapeutics (NASDAQ:OTLK) Inc ended its fiscal second quarter with $58.4 million in cash – enough to launch its lead drug ONS-5010 without raising significant additional capital, it said. ONS-5010, which will be sold under the brand name Lytenava, is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases.
2022-05-10 10:08:50 - Proactive Investors
Outlook Therapeutics says its COO to talk wet AMD drug Lytenava at World Retina Conference this week
Outlook Therapeutics (NASDAQ:OTLK) Inc has said its chief operations officer Terry Dagnon will discuss the company's wet age-related macular degeneration (AMD) drug Lytenava as part of a panel at the 2022 World Retina Conference later this month. The conference is taking place from May 12-15, 2022, in Fort Lauderdale, Florida.
2022-04-22 09:36:07 - Proactive Investors
Outlook Therapeutics says BioLexis reorganization results in GMS Holdings becoming its largest shareholder
Outlook Therapeutics (NASDAQ:OTLK) Inc revealed that BioLexis Private Limited, a strategic shareholder in the pre-commercial biopharmaceutical company, is being reorganized and has resulted in GMS Holdings emerging as its largest shareholder. The Singapore and Iselin, New Jersey-based biopharma company noted that the BioLexis reorganization, which does not entail any changes in the indirect ownership of Outlook Therapeutics (NASDAQ:OTLK), provides GMS Holdings with “increased flexibility” to support Outlook's growth as its largest shareholder.
2022-03-31 09:23:52 - Proactive Investors
Outlook Therapeutics submits Biologics License Application to US FDA for its investigational therapy to treat wet age-related macular degeneration
Outlook Therapeutics (NASDAQ:OTLK) Inc said it has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ONS-5010, an investigational therapy for the treatment of wet age-related macular degeneration (wet AMD). If approved, the treatment will be branded as LYTENAVA (bevacizumab-vikg) and could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies, products that have known risks of contamination and inconsistent potency and availability.
2022-02-17 12:24:30 - PennyStocks
Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up
Biotech penny stocks to watch as Ukraine-Russia conflict builds steam. The post Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-02-01 15:05:35 - PennyStocks
3 Top Penny Stocks To Buy For Under $5 Today
Are these on your list of penny stocks to watch right now? The post 3 Top Penny Stocks To Buy For Under $5 Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.